QIBA PET Amyloid Biomarker Committee
19 June 2015 at 9:00 AM CT (GMT-6)

In attendance:  

Participants:    RSNA

Co-chairs:  

Ronald Boellaard, PhD    Dawn Matthews, MS, MBA    Joe Koudelik
Satoshi Minoshima, MD, PhD    Constantine Gatsonis, PhD    Huseyin Toré, MD    Julie Lisiecki
Eric Perlman, MD    John Hoffman, MD    Jean-Luc Vanderheyden, PhD
Gregory Klein, PhD    Richard Wahl, MD, FACC
Martin Lodge, PhD

Call Summary Points and Action Items:

• Status overview of the Profile draft review in progress by Dr. Perlman
• Mechanism for submitting comments via Excel document was discussed
  o Group to review sections using the spreadsheet for comments, focusing on Section 3.4
    ▪ Drop-down selection re: standardized comments for Profile editing was demonstrated
    ▪ Importance of not changing line numbers within the Profile document was stressed
• Ad hoc t-cons to be planned prior to the next Amyloid BC call to continue progress with Profile comment resolution
• Dr. Perlman to collate feedback for discussion

Claim Language:

• Progress dependent on meta-analysis work being done by experts: Drs. Subramaniam, Frey, and Obuchowski
  o Group plans to continue moving forward with the literature review
• Both cross-sectional and longitudinal claims to be used; cross-sectional claim is on hold for now, pending an estimation of bias
  o A longitudinal claim can be achieved without estimation of bias, but with reliance on the scientific literature and repeatability coefficients, e.g., percent change in measurand over multiple time points
  o Dr. Subramaniam’s proposed Round-5 funded meta-analysis project is awaiting Steering Cmte approval; however, work is to continue in the interim

Amyloid Phantoms and DRO Uses:

• Drs. Kinahan and Sunderland working to complete Round-4 projects for the amyloid DRO and physical phantom respectively
  o These may be used in conjunction with the Profile to measure “conformance”
  o A more specific DRO developed for PET Amyloid imaging will be used for future Profile releases
  o DROs to be used in conjunction with physical phantoms for accuracy

Upcoming Nuclear Medicine Calls (Fridays, 9 am CT):

• June 26: NM Combination BC Call
• July 3:  No call. RSNA Offices Closed.
• July 10: FDG-PET Biomarker Ctte
• July 17: Amyloid Biomarker Ctte
• July 24: SPECT Biomarker Ctte
• July 31: NM Combination BC Call